Placebo News and Research

RSS

Treating SIBO holistically helps patients feel better, new study finds

A 90-day real-world study in Spain shows that a comprehensive, personalized treatment for SIBO significantly improves patients’ quality of life—even when breath tests remain abnormal.

7 Apr 2025

Reducing cardiometabolic risk and inflammation with pomegranate

Pomegranate extract shows promise in lowering systolic blood pressure and inflammatory markers, highlighting its role in promoting healthy aging for adults 55+.

4 Apr 2025

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR reduced the relative risk of major morbidity and mortality events (the composite of all-cause death, lung transplantation and PAH worsening-related hospitalization of ≥24 hours) by 76% (HR=0.24 [95% CI, 0.13-0.43]; p<0.0001 [1-sided]) compared to placebo.

1 Apr 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

1 Apr 2025

Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in JACC.

31 Mar 2025

What blueberries do and don’t do for your microbiome and heart

Regular blueberry consumption for 12 weeks enriched Coriobacteriales incertae sedis in the gut microbiota of older overweight adults. However, this microbial shift was not linked to significant improvements in cardiometabolic biomarkers.

31 Mar 2025

‘They won’t help me’: Sickest patients face insurance denials despite policy fixes

Sheldon Ekirch spends a lot of time on hold with her health insurance company. Sometimes, as the minutes tick by and her frustration mounts, Ekirch, 30, opens a meditation app on her phone. It was recommended by her psychologist to help with the depression associated with a stressful and painful medical disorder.

31 Mar 2025

$Intravenous iron shows promise for heart failure with reduced ejection fraction$

Intravenous iron shows promise for heart failure with reduced ejection fraction

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

31 Mar 2025

Investigational drug lorundrostat offers significant blood pressure drop compared with placebo

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

31 Mar 2025

Caffeine and beetroot juice beat fatigue in repeated high-intensity runs

Caffeine combined with beetroot juice significantly improves both initial and repeated 1000-meter running performance in non-athlete men. Body fat percentage, sleep duration, and nutrition emerge as key factors influencing endurance outcomes.

30 Mar 2025

Bentracimab reverses ticagrelor's antiplatelet effects during surgery and bleeding events

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major bleeding, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

29 Mar 2025

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD.

29 Mar 2025

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

26 Mar 2025

Women with premenstrual syndrome appear to find relief from symptoms with placebos

Women affected by premenstrual syndrome (PMS) appear to experience less intense and debilitating symptoms after taking placebo pills even when told they do not contain any active medication, suggests a study published in the open-access journal BMJ Evidence-Based Medicine.

25 Mar 2025

Fish oil supplements beat oily fish at reducing harmful blood vesicles

Fish oil supplements, delivering higher EPA doses, significantly reduced the number and procoagulant activity of extracellular vesicles—unlike oily fish. This suggests EPA, not DHA, may drive cardiovascular benefits linked to EV function.

24 Mar 2025

Eye drops show potential to slow progression of human degenerative retinal diseases

Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa.

21 Mar 2025

Strawberries enhance brain speed and heart health, but cognitive benefits remain unclear

Strawberries may modestly enhance processing speed and lower systolic blood pressure in older adults, but they do not significantly improve overall cognitive function or vascular health.

19 Mar 2025

Experimental drug shows promise in reducing risk of Alzheimer's-related dementia

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis.

19 Mar 2025

Clinical trial investigates osteoporosis medication for type 1 diabetes

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a top research center for diabetes and other life-threatening illnesses, is leading a phase 1/2 clinical trial investigating an osteoporosis medication as a way to improve beta cell health in people with early type 1 diabetes.

19 Mar 2025

Placebo News and Research

Treating SIBO holistically helps patients feel better, new study finds

Reducing cardiometabolic risk and inflammation with pomegranate

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

What blueberries do and don’t do for your microbiome and heart

‘They won’t help me’: Sickest patients face insurance denials despite policy fixes

Intravenous iron shows promise for heart failure with reduced ejection fraction

Investigational drug lorundrostat offers significant blood pressure drop compared with placebo

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Caffeine and beetroot juice beat fatigue in repeated high-intensity runs

Bentracimab reverses ticagrelor's antiplatelet effects during surgery and bleeding events

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Women with premenstrual syndrome appear to find relief from symptoms with placebos

Fish oil supplements beat oily fish at reducing harmful blood vesicles

Eye drops show potential to slow progression of human degenerative retinal diseases

Strawberries enhance brain speed and heart health, but cognitive benefits remain unclear

Experimental drug shows promise in reducing risk of Alzheimer's-related dementia

Clinical trial investigates osteoporosis medication for type 1 diabetes

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News